Citi Upgrades Merck (MRK) to Buy Following Positive Odanacatib News
Tweet
Share
E-mailGet Alerts MRK Hot Sheet
Price: $152.34 +0.46%
Rating Summary:
24 Buy, 7 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 5 | Down: 18 | New: 28
Rating Summary:
24 Buy, 7 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 5 | Down: 18 | New: 28
Join SI Premium – FREE
Citi upgraded Merck (NYSE: MRK) from Neutral to Buy.
The upgrade follows positive odanacatib Phase III news late on Wednesday.
Shares of Merck are up 2.8 percent at last check.
For an analyst ratings summary and ratings history on Merck click here. For more ratings news on Merck click here.
The upgrade follows positive odanacatib Phase III news late on Wednesday.
Shares of Merck are up 2.8 percent at last check.
For an analyst ratings summary and ratings history on Merck click here. For more ratings news on Merck click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Macquarie Upgrades Broadcom Limited (AVGO) to Outperform
- CLSA Upgrades Taiyo Yuden Co Ltd (6976:JP) (TYOYY) to High-Conviction Outperform (1)
- JPMorgan Upgrades Envista Holdings Corp. (NVST) to Overweight
Create E-mail Alert Related Categories
UpgradesRelated Entities
CitiSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
